| |||
|
ÌÅÄËÀÉÍ.ÐÓ
|
|||
|
Êëèíè÷åñêàÿ ìåäèöèíà » Òåðàïèÿ • Èíôåêöèîííûå áîëåçíè
Òîì: 11 Ñòàòüÿ: « 47 » Ñòðàíèöû:. 554-574 Îïóáëèêîâàíà â æóðíàëå: äåêàáðü 2010 ã. English version 
¹ ãîñ. ðåãèñòðàöèè: 0421000002 047 Èììóíîãåíåòè÷åñêèå ôàêòîðû ïàòîãåíåçà HCV−èíôåêöèèÐîìàíîâ À.Î., Áåëÿåâà Ò.Â., Ýñàóëåíêî Å.Â.
Ñàíêò-Ïåòåðáóðãñêèé ãîñóäàðñòâåííûé ìåäèöèíñêèé óíèâåðñèòåò èì. àêàä. È.Ï. Ïàâëîâà
Ðåçþìå
Âèðóñ ãåïàòèòà Ñ îáëàäàåò âûñîêîé ñïîñîáíîñòüþ ê ïåðñèñòåíöèè è âûçûâàåò õðîíè÷åñêèé ãåïàòèò ñ ïîâûøåííûì ðèñêîì ðàçâèòèÿ öèððîçà. Èììóííûé îòâåò îðãàíèçìà èìååò óíèêàëüíóþ ðîëü, òàê êàê íå òîëüêî ýëèìèíèðóåò âèðóñ, íî è âûçûâàåò ïîâðåæäåíèå ïå÷åíè.  ñòàòüå ðàññìàòðèâàþòñÿ èììóíîãåíåòè÷åñêèå ôàêòîðû, íå îòíîñÿùèåñÿ ê ñèñòåìå HLA, ñ öåëüþ ïîêàçàòü êàê èììóííàÿ ñèñòåìà õîçÿèíà âçàèìîäåéñòâóåò ñ âèðóñíûìè êîìïîíåíòàìè. Êëþ÷åâûå ñëîâà ãåïàòèò Ñ; öèððîç; èììóíîãåíåòèêà, CTLA-4, MBL. (ñòàòüÿ â ôîðìàòå PDF. Äëÿ ïðîñìîòðà íåîáõîäèì Adobe Acrobat Reader)  îòêðûòü ñòàòüþ â íîâîì îêíå
Ñïèñîê ëèòåðàòóðû 1. Abrams J.R., Kelley S.L., Hayes E. et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells // J. Exp. Med. – 2000. – Vol. 192, ¹5. – Ð. 681 – 694. 2. Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome // Semin Liver Dis. – 2000. – Vol. 20, ¹1. – P. 17 – 35. 3. Alves Pedroso M.L., Boldt A.B., Pereira-Ferrari L, et al. Mannan-binding lectin MBL2 gene polymorphism in chronic hepatitis C: association with the severity of liver fibrosis and response to interferon therapy // Clin. Exp. Immunol. – 2008. – Vol. 152, ¹2. – Ð. 258 – 264. 4. Bisbal C., Silverman R.H. Diverse functions of RNase L and implications in pathology // Biochimie. – 2007. – Vol. 89, ¹ 6-7. – Ð. 789 – 798. 5. Bour-Jordan H., Bluestone J.A. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells // Immunol. Rev. – 2009. Vol. 229, ¹1. – Ð. 41 – 66. 6. Brown E.E., Zhang M., Zarin-Pass R., et al. MBL2 and hepatitis C virus infection among injection drug users // BMC Infect. Dis. – 2008. – Vol. 1, ¹8. – Ð. 57. 7. Brown K.S., Ryder S.D., Irving W.L., et al. Mannan binding lectin and viral hepatitis // Immunol. Lett. – 2007. – Vol. 108, ¹1. – P. 34 – 44. 8. Carreno B.M., Bennett F., Chau T.A. et al. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surfaceexpression // J. Immunol. – 2000. – Vol. 165, ¹3. – P. 1352 – 1356. 9. Casey G., Neville P.J., Plummer S.J. et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases // Nat. Genet. – 2002. – Vol. 32, ¹4. – Ð. 581 – 583. 10. Cedzynski M., Szemraj J., Swierzko A.S. et al. Mannan-binding lectin insufficiency in children with recurrent infections of the respiratory system // Clin. Exp. Immunol. – 2004. – Vol. 136, ¹2. – Ð. 304 – 311. 11. Chambers C.A., Sullivan T.J., Allison J.P. Lymphoproliferation in CTLA-4- deficient mice is mediated by costimulation-dependent activation of CD4+ T cells // Immunity. – 1997. – Vol. 7, ¹6. – Ð. 885 – 895. 12. Chaplin D.D. Overview of the immune response // J. Allergy Clin. Immunol. – 2010. – Vol. 125, ¹2, Suppl. 2. – Ð. 3 – 23. 13. Cho M.L., Kim J.Y., Ko H.J. et al. The MCP-1 promoter -2518 polymorphism in Behcet's disease: correlation between allele types, MCP-1 production and clinical symptoms among Korean patients // Autoimmunity. – 2004. – Vol. 37, ¹1. – Ð. 77 – 80. 14. Collins M., Ling V., Carreno B.M. The B7 family of immune-regulatory ligands // Genome. Biol. – 2005 – Vol. 6, ¹6. – Ð. 223. 15. Crawford A., Wherry E.J. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses // Curr. Opin. Immunol. – 2009. – Vol. 21, ¹2. – Ð. 179 – 186. 16. Dariavach P., Mattei M.G., Golstein P., Lefranc MP. Human Ig superfamily CTLA- 4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains // Eur. J. Immunol. – 1988. – Vol. 18, ¹12. – Ð. 1901 – 1905. 17. Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte chemoattractant protein-1 (MCP-1): an overview // J. Interferon Cytokine Res. – 2009. – Vol. 29, ¹6. – Ð. 313 – 326. 18. Dobaczewski M., Frangogiannis N.G. Chemokines and cardiac fibrosis // Front. Biosci. – 2009. – Vol. 1, ¹1. – Ð. 391 – 405. 19. Donner H., Seidl C., Braun J. et al. CTLA4 gene haplotypes cannot protect from IDDM in the presence of high-risk HLA DQ8 or DQ2 alleles in German families // Diabetes. – 1998. – Vol. 47, ¹7. – Ð. 1158 – 1160. 20. Dore G.J., Freeman A.J., Law M., Kaldor J.M. Is severe liver disease a common outcome for people with chronic hepatitis C? // J. Gastroenterol. Hepatol. – 2002. – Vol. 17, ¹4. – Ð. 423 – 430. 21. Dumestre-Perard C., Ponard D., Arlaud G.J. et al. Evaluation and clinical interest of mannan binding lectin function in human plasma // Mol. Immunol. – 2002. – Vol. 39, ¹ 7-8. – Ð. 465 – 473. 22. Dunkelberger J.R., Song W.C. Complement and its role in innate and adaptive immune responses // Cel.l Res. – 2010. - – Vol. 20, ¹ 1. – Ð. 34 – 50. 23. Dunning A.M., Ellis P.D., McBride S. A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer // Cancer Res. – 2003. – Vol. 63, ¹ 10 – Ð. 2610 – 2615 24. Finzer P., Soto U., Delius H. et al. Differential transcriptional regulation of the monocyte-chemoattractant protein-1 (MCP-1) gene in tumorigenic and non-tumorigenic HPV 18 positive cells: the role of the chromatin structure and AP-1 composition // Oncogene – 2000. – Vol. 19, ¹ 29. – Ð. 3235 – 3244. 25. Friedman S.L. Liver fibrosis - from bench to bedside // J. Hepatol. – 2003. – Vol. 38, Suppl 1. – P. 38 – 53. 26. Garred P., Madsen H.O. Genetic Susceptibility to Sepsis: A Possible Role for Mannose-binding Lectin // Curr. Infect Dis. Rep. – 2004 – Vol. 6, ¹ 5. – Ð. 367 – 373. 27. Garred P., Pressler T., Lanng S. et al. Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease // Pediatr. Pulmonol. – 2002. – Vol. 33, ¹ 3. – Ð. 201 -207. 28. Gewaltig J., Mangasser-Stephan K., Gartung C. et al. Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCV-induced liver fibrosis // Clin. Chim. Acta. – 2002. – Vol. 316, ¹ 1-2. – Ð. 83 – 94. 29. Glas J., Torok H.P., Tonenchi L. et al. The -2518 promotor polymorphism in the MCP-1 gene is not associated with liver cirrhosis in chronic hepatitis C virus infection // Gastroenterology. – 2004. – Vol. 126, ¹ 7. – Ð. 1930 – 1931. 30. Gleizes P.E., Munger J.S., Nunes I. et al. TGF-beta latency: biological significance and mechanisms of activation // Stem. Cells. – 1997. – Vol. 15, ¹ 3. – Ð. 190 – 197. 31. Hardie W.D., Le Cras T.D., Jiang K. et al. Conditional expression of transforming growth factor-alpha in adult mouse lung causes pulmonary fibrosis // Am. J. Physiol. Lung Cell. Mol. Physiol. – 2004. – Vol. 286, ¹ 4. – Ð. 741 – 749. 32. Hart M.L., Saifuddin M., Spear G.T. Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding lectin // J. Gen. Virol. – 2003. – Vol. 84, ¹ 2. – Ð. 353 – 360. 33. Kilpatrick D.C., Delahooke T.E., Koch C., Turner M.L., Hayes P.C. Mannanbinding lectin and hepatitis C infection // Clin. Exp. Immunol. – 2003. – Vol. 132, ¹ 1 – Ð. 92 – 95. 34. Hodi F.S. Cytotoxic T-lymphocyte-associated antigen-4 // Clin. Cancer Res. – 2007. – Vol. 13, ¹ 18, Suppel. 1. – Ð. 5238 – 5242. 35. Hokeness K.L., Kuziel W.A., Biron C.A., Salazar-Mather T.P. Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-alpha/beta-induced inflammatory responses and antiviral defense in liver // J. Immunol. – 2005. – Vol. 174, ¹ 3. – Ð. 1549 – 1556. 36. Ip W.K., Lau Y.L. Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells // J. Infect. Dis. – 2004. – Vol. 190, ¹ 3. – Ð. 632 – 640. 37. Karrer S., Bosserhoff A.K., Weiderer P. et al. The -2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis // J. Invest. Dermatol. – 2005. – Vol. 124, ¹ 1. – Ð. 92 – 98. 38. Kelly P., Jack D.L., Naeem A. et al. Mannose-binding lectin is a component of innate mucosal defense against Cryptosporidium parvum in AIDS // Gastroenterology. – 2000. – Vol. 119, ¹ 5. – Ð. 1236 – 1242. 39. Kinnman N., Andersson U., Hultcrantz R. In situ expression of transforming growth factor-beta1-3, latent transforming growth factor-beta binding protein and tumor necrosis factoralpha in liver tissue from patients with chronic hepatitis C // Scand. J. Gastroenterol. – 2000. – Vol. 35, ¹ 12. – Ð. 1294 – 1300. 40. Kouki T., Gardine C.A., Yanagawa T., Degroot L.J. Relation of three polymorphisms of the CTLA-4 gene in patients with Graves’disease // J. Endocrinol. Invest. – 2002. – Vol. 25, ¹ 3. – Ð. 208 – 213. 41. Koutsounaki E., Goulielmos G.N., Koulentaki M., et al. Mannose-binding lectin MBL2 gene polymorphisms and outcome of hepatitis C virus-infected patients // J. Clin. Immunol. – 2008. – Vol. 28, ¹ 5. – Ð. 495 – 500. 42. Larsen F., Madsen H.O., Sim R.B. et al. Disease-associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein // J. Biol. Chem. – 2004. – Vol. 14, ¹ 20. – Ð. 21302 – 21311. 43. Le Roy F., Silhol M., Salehzada T., Bisbal C. Regulation of mitochondrial mRNA stability by RNase L is translation-dependent and controls IFNalpha-induced apoptosis // Cell. Death Differ. – 2007. – Vol. 14, ¹ 8. – Ð. 1406 – 1413. 44. Letendre S., Marquie-Beck J., Singh K.K. et al. The monocyte chemotactic protein-1 -2578G allele is associated with elevated MCP-1 concentrations in cerebrospinal fluid // J. Neuroimmunol. – 2004. – Vol. 157, ¹ (1-2). – Ð. 193 – 196. 45. Ligers A., Teleshova N., Masterman T. et al. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms // Genes Immun. – 2001. – Vol. 2, ¹ 3. – Ð. 145 – 152. 46. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation // N. Engl. J. Med. – 1998. – Vol. 338, ¹ 7. – Ð. 436 – 445. 47. Markiewski M.M., Lambris J.D. The role of complement in inflammatory diseases from behind the scenes into the spotlight // Am. J. Pathol. – 2007. – Vol. 171, ¹ 3. – Ð. 715 – 727. 48. Martin P., Lerner A., Johnson L. et al. Inherited mannose-binding lectin deficiency as evidenced by genetic and immunologic analyses: association with severe recurrent infections // Ann. Allergy Asthma Immunol. – 2003. – Vol. 91, ¹ 4. – Ð. 386 – 392. 49. Matsushita M., Hijikata M., Ohta Y. et al. Hepatitis C virus infection and mutations of mannose-binding lectin gene MBL // Arch. Virol. – 1998. – Vol. 143, ¹ 4. – Ð. 645 – 651. 50. Matsushita M., Hijikata M., Matsushita M. et al. Association of mannose-binding lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in Japanese patients // J. Hepatol. – 1998. – Vol. 29, ¹ 5. – Ð. 695 – 700 51. Maurer M., Loserth S., Kolb-Maurer A. et al. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1+49) alters T-cell activation // Immunogenetics. – 2002. – Vol. 54, ¹ 1. – Ð. 1 – 8 52. Muhlbauer M., Bosserhoff A.K., Hartmann A. et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease // Gastroenterology. – 2003. – Vol. 125, ¹4. – Ð. 1085 – 1093. 53. Nahon P, Sutton A., Rufat P., et al. Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis // World J. Gastroenterol. – 2008. – Vol. 14, ¹ 5. – Ð. 713 – 719. 54. Najafian N., Sayegh M.H. CTLA4-Ig: a novel immunosuppressive agent // Expert. Opin. Investig. Drugs. – 2000. – Vol. 9, ¹ 9. – Ð. 2147 – 2157. 55. NIH Consensus Statement on Management of Hepatitis C: 2002 NIH Consensus and State-of-the-Science Statements. – 2002, – Vol. 19, ¹3, – Ð.30. 56. Oaks M.K., Hallett K.M., Penwell R.T. et al. A native soluble form of CTLA-4 // Cell Immunol. – 2000. – Vol. 201, ¹ 2. – Ð. 144 – 153. 57. Ostrov D.A., Shi W., Schwartz J.C. et al. Structure of murine CTLA-4 and its role in modulating T cell responsiveness // Science. – 2000. – Vol. 290, ¹ 5492. – Ð. 816 – 819. 58. Pangburn M.K., Ferreira V.P., Cortes C. Discrimination between host and pathogens by the complement system // Vaccine. – 2008. Vol. 26, Suppl 8. – P. 15 – 21. 59. Park Y.J., Chung H.K., Park D.J. et al. Polymorphism in the promoter and exon 1 of thecytotoxic T lymphocyte antigen-4 gene associated with autoimmune thyroid disease in Koreans // Thyroid. – 2000. – Vol. 10, ¹ 6. – Ð. 453 – 459. 60. Patel K., Muir A.J., McHutchison J.G. Diagnosis and treatment of chronic hepatitis C infection // BMJ. – 2006. – Vol. 332, ¹ 7548. – Ð. 1013 – 1017. 61. Peterslund N.A., Koch C., Jensenius J.C., Thiel S. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy // Lancet. – 2001. – Vol. 358, ¹ 9282. – Ð. 637 – 638. 62. Petri B., Phillipson M., Kubes P. The physiology of leukocyte recruitment: an in vivo perspective // J. Immunol. – 2008. – Vol. 180, ¹ 10. – Ð. 6439 – 6446. 63. Powell E.E., Edwards-Smith C.J., Hay J.L., Host genetic factors influence disease progression in chronic hepatitis C // Hepatology. – 2000. – Vol. 31, ¹ 4. – Ð. 828 – 833 64. Poynard T., Ratziu V., Benmanov Y., Fibrosis in patients with chronic hepatitis C: detection and significance // Semin. Liver Dis. – 2000. – Vol. 20, ¹ 1. – Ð. 47 – 55. 65. Randall R.E., Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures // J. Gen. Virol. – 2008. – Vol. 89, ¹ 1. – Ð. 1 – 47. 66. Ray S., Broor S.L., Vaishnav Y. et al. Transforming growth factor beta in hepatitis C virus infection: in vivo and in vitro findings // J. Gastroenterol. Hepatol. – 2003. – Vol. 18, ¹ 4. – Ð. 393 – 403. 67. Rovin B.H., Lu L., Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression // Biochem. Bioph. Res. Com. – 1999. – Vol. 259. – Ð. 344 – 348. 68. Roy S., Knox K., Segal S. et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study // Lancet. – 2002. – Vol. 359, ¹ 9317. – Ð. 1569 – 1573. 69. Rudd C.E., Taylor A., Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction // Immunol. Rev. – 2009. – Vol. 229, ¹ 1. – Ð. 12 – 26. 70. Sadler A.J., Williams B.R. Interferon-inducible antiviral effectors // Nat. Rev. Immunol. – 2008. – Vol. 8, ¹ 7. – Ð. 559 – 568. 71. Sasaki K., Tsutsumi A., Wakamiya N. et al. Mannose-binding lectin polymorphisms in patients with hepatitis C virus infection // Scand. J. Gastroenterol. – 2000. – Vol. 35, ¹ 9. – Ð. 960 – 965. 72. Segat L., Silva Vasconcelos L.R., et al. Association of polymorphisms in the first exon of mannose binding lectin gene (MBL2) in Brazilian patients with HCV infection // Clin. Immunol. – 2007. – Vol. 124, ¹ 1. – Ð. 13 – 17. 73. Seki E., de Minicis S., Inokuchi S., Taura K., Miyai K., van Rooijen N., Schwabe R.F., Brenner D.A. CCR2 promotes hepatic fibrosis in mice // Hepatology. – 2009. – Vol. 50, ¹ 1. – Ð. 185 – 197. 74. Si Y., Tsou C.L., Croft K., Charo I.F. CCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in mice // J. Clin. Invest. – 2010. – Vol. 120, ¹ 4. – Ð. 1192 – 1203. 75. Silverman R.H. A scientific journey through the 2-5A/RNase L system // Cytokine Growth. Factor Rev. – 2007. – Vol. 18, ¹ 5-6. – Ð. 381 – 388. 76. Silverman R.H. Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response // J. Virol. – 2007. – Vol. 81, ¹ 23. – Ð. 12720 – 12729. 77. Soo H.M., Garzino-Demo A., Hong W. et al. Expression of a full-length hepatitis C virus cDNA up-regulates the expression of CC chemokines MCP-1 and RANTES // Virology. – 2002. – Vol. 303, ¹ 2. – Ð. 253 – 277. 78. Sumiya M., Super M., Tabona P. et al. Molecular basis of opsonic defect in immunodeficient children // Lancet. – 1991. – Vol. 337, ¹ 8757. – Ð. 1569 – 1570. 79. Summerfield J.A., Ryder S., Sumiya M. et al. Mannose binding protein gene mutations associated with unusual and severe infections in adults // Lancet. – 1995. – Vol. 345, ¹ 8954. – Ð. 886 – 889. 80. Summerfield J.A., Sumiya M., Levin M., Turner M.W. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series // BMJ. – 1997. – Vol. 314, ¹ 7089. – Ð. 1229 – 1232. 81. Tag C.G., Mengsteab S., Hellerbrand C. et al. Analysis of the transforming growth factor-beta1 (TGF-beta1) codon 25 gene polymorphism by LightCycler-analysis in patients with chronic hepatitis C infection // Cytokine. – 2003. – Vol. 24, ¹ 5. – Ð. 173 – 181. 82. Taylor A.W. Review of the activation of TGF-beta in immunity // J. Leukoc. Biol. – 2009. – Vol. 85, ¹ 1. – Ð. 29 – 33. 83. Terai I., Kobayashi K., Matsushita M. et al. Relationship between gene polymorphisms of mannose-binding lectin (MBL) and two molecular forms of MBL // Eur. J. Immunol. – 2003. – Vol. 33, ¹ 10. – Ð. 2755 – 2763. 84. Thompson C.B., Allison J.P. The emerging role of CTLA-4 as an immune attenuator // Immunity. – 1997. – Vol. 7, ¹ 4. – Ð. 445 – 450. 85. Vaidya B., Oakes E.J., Imrie H. et al. CTLA4 gene and Graves' disease: association of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism // Clin. Endocrinol. – 2003. – Vol. 58, ¹ 6. – Ð. 732 – 735. 86. Valdimarsson H., Stefansson M., Vikingsdottir T. et al. Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans // Scand. J. Immunol. – 1998. – Vol. 48, ¹ 2. – Ð. 116 – 123. 87. Valdimarsson H., Vikingsdottir T., Bang P. et al. Human plasma-derived mannosebinding lectin: a phase I safety and pharmacokinetic study // Scand. J. Immunol. – 2004. – Vol. 59, ¹ 1. – Ð. 97 – 102. 88. Valdimarsson H. Infusion of plasma-derived mannan-binding lectin (MBL) into MBL-deficient humans // Biochem. Soc. Trans. – 2003. – Vol. 31, ¹ 4. – Ð. 768 – 769. 89. van de Wetering J.K., van Golde L.M., Batenburg J.J. Collectins: players of the innate immune system // Eur. J. Biochem. – 2004. – Vol. 271, ¹ 7. – Ð. 1229 – 1249. 90. Van Parijs L., Abbas A.K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off // Science. – 1998. – Vol. 280, ¹ 5361. – Ð. 243 – 248. 91. Verrecchia F., Mauviel A. Transforming growth factor-beta and fibrosis // World J. Gastroenterol. – 2007. – Vol. 13, ¹ 22. – Ð. 3056 – 3062. 92. Vidigal P.G., Germer J.J., Zein N.N. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin // J. Hepatol. – 2002. – Vol. 36, ¹ 2. – Ð. 271 – 277. 93. Wang H., Mengsteab S., Tag C.G. et al. Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection // World J G.astroenterol. – 2005. – Vol. 11, ¹ 13. – Ð. 1929 – 1936. 94. Wang S., Chen L. T lymphocyte co-signaling pathways of the B7-CD28 family // Cell. Mol. Immunol. – 2004. – Vol. 1, ¹ 1. – Ð. 37 – 42. 95. Washenberger C.L., Han J.Q., Kechris K.J., Jha B.K., Silverman R.H., Barton D.J. Hepatitis C virus RNA: dinucleotide frequencies and cleavage by RNase L // Virus Res. – 2007. – Vol. 130, ¹ 1–2. – Ð. 85 – 95. 96. Wynn T.A. Cellular and molecular mechanisms of fibrosis // J. Pathol. – 2008. – Vol. 214, ¹ 2. – Ð. 199 – 210. 97. Xiang Y., Wang Z., Murakami J. et al. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates // Cancer Res. – 2003. – Vol. 63, ¹ 20. – Ð. 6795 – 67801. 98. Yee L.J., Perez K.A., Tang J. et al. Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection // J. Infect. Dis. – 2003. – Vol. 187, ¹ 8. – Ð. 1264 – 1271. 99. Yokota M., Ichihara S., Lin T.L. et al. Association of a T29-->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese // Circulation. – 2000. – Vol. 101, ¹ 24. – Ð. 2783 – 2787 | ||
| |||
Ôåäåðàëüíîå ãîñóäàðñòâåííîå áþäæåòíîå ó÷ðåæäåíèå íàóêè